Study tests if patients grasp their own Alzheimer's biomarker news

NCT ID NCT04818255

Completed Knowledge-focused Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether people with mild cognitive impairment or Alzheimer's-type dementia can understand and decide about receiving their PET scan results for amyloid and tau proteins. Researchers educated 152 participants and their care partners, then assessed their ability to make an informed choice. The goal was to learn how to best share this sensitive biomarker information.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors and families better understand how to share Alzheimer's risk information in a way that patients can understand and use.
What could go wrong: This is a small, completed study focused on education and decision-making, not treatment. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEMENTIA; ALZHEIMER'S TYPE (ETIOLOGY) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEMENTIA; ALZHEIMER'S TYPE (ETIOLOGY) MILD COGNITIVE IMPAIRMENT

Contacts and locations

Locations

University of Michigan Medical School, Department of Psychiatry

Ann Arbor, Michigan, 48105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.